NCT02575261 2020-07-16CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma PatientsFuda Cancer Hospital, GuangzhouPhase 1/2 Withdrawn
NCT03638206 2019-12-11Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesShenzhen BinDeBio Ltd.Phase 1/2 Unknown73 enrolled